Combretastatin A1 phosphate

Drug Profile

Combretastatin A1 phosphate

Alternative Names: CA1; CA1P; Combrestatin A1 diphosphate; Combretastatin A1 di-phosphate; OXi 4503

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics
  • Class Antineoplastics; Combretastatins; Diphosphates; Stilbenes
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Liver cancer; Liver metastases; Myelodysplastic syndromes
  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2017 Efficacy and adverse events data from a phase Ib/II trial in Acute myeloid leukaemia or Myelodysplastic syndrome released by Mateon Therapeutics
  • 03 Dec 2016 Efficacy and adverse events data from a phase Ib/II trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top